Gilead Sciences
$144.74Change from previous close: −1.87%Absolute change: −$2.76
At a glance
- Revenue growth
- +2.40%
- 2025 vs 2024
- Net income growth
- +1,672.92%
- 2025 vs 2024
- Net margin
- 28.9%
- 2024: 1.7%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 29,443 | 28,754 | 27,116 | 27,281 | 27,305 |
| Cost of revenue | 6,230 | 6,251 | 5,968 | 5,657 | 5,526 |
| Gross profit | 23,213 | 22,503 | 21,148 | 21,624 | 21,779 |
| Selling, general and administrative | 5,708 | 6,000 | 6,062 | 5,673 | 5,246 |
| Research and development | 5,688 | 5,816 | 5,758 | 4,977 | 4,601 |
| Operating income | 11,817 | 10,687 | 9,328 | 10,974 | 11,932 |
| EBIT | 11,817 | 10,687 | 9,328 | 10,974 | 11,932 |
| EBITDA | 14,577 | 13,454 | 12,021 | 13,077 | 13,982 |
| Interest expense | 1,024 | 977 | 944 | 935 | 1,001 |
| Pre-tax income | 9,796 | 691 | 6,860 | 5,814 | 8,278 |
| Income tax | 1,286 | 211 | 1,247 | 1,248 | 2,077 |
| Net income | 8,510 | 480 | 5,665 | 4,592 | 6,225 |
| Net income to common shareholders | 8,510 | 480 | 5,665 | 4,592 | 6,225 |
| Basic EPS | 6.84 | 0.38 | 4.54 | 3.66 | 4.96 |
| Diluted EPS | 6.78 | 0.38 | 4.50 | 3.64 | 4.93 |
| Average shares (basic) | 1,244 | 1,247 | 1,248 | 1,255 | 1,256 |
| Average shares (diluted) | 1,255 | 1,255 | 1,258 | 1,262 | 1,262 |
| Dividend per share | 3.16 | 3.08 | 3.00 | 2.92 | 2.84 |